SCHOTT Pharma AG & Co. KGaA is a leading global provider of pharmaceutical packaging solutions, specializing in primary drug containment and delivery systems for injectable medications. Headquartered ... SCHOTT Pharma AG & Co. KGaA is a leading global provider of pharmaceutical packaging solutions, specializing in primary drug containment and delivery systems for injectable medications. Headquartered in Mainz, Germany, the company draws on over 130 years of expertise in glass science as part of the SCHOTT AG group, employing around 4,700 people across 16 GMP-compliant manufacturing sites in Europe, North America, South America, and Asia. Its core portfolio includes high-quality vials, syringes, cartridges, and ampoules made from Type I borosilicate glass or medical-grade cyclic olefin copolymer (COC) polymer, such as the syriQ® glass syringes, TOPPAC® polymer syringes, cartriQ® cartridges, and innovative EVERIC® vials. These products ensure drug stability for biologics, vaccines, and mRNA therapies, even under ultra-cold storage, while minimizing interactions and supporting efficient fill-finish processes. SCHOTT Pharma also offers value-added services like packaging design, regulatory support, and sustainability initiatives. In the financial markets, it plays a vital role supplying pharmaceutical and biotechnology firms, enabling safe, reliable drug delivery amid rising demand for advanced injectables.
In 2025, SCHOTT Pharma AG & Co was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
SCHOTT Pharma AG & Co has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of SCHOTT Pharma AG & Co are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
Metric (tonnes)
2025
2024
2023
2022 - 2017
Total Taxonomy Aligned A1 Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible A Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Non-Eligible B Turnover
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Metric (tonnes)
2025
2024
2023
2022 - 2017
Total Taxonomy Aligned A1 Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible A Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Non-Eligible B Opex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
6.5 CCM/CCA - Transport by motorbikes, passenger cars and light commercial vehicles
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Metric (tonnes)
2025
2024
2023
2022 - 2017
Total Taxonomy Aligned A1 Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible A Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Non-Eligible B Capex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
6.5 CCM/CCA - Transport by motorbikes, passenger cars and light commercial vehicles
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
7.3 CCM/CCA - Installation, maintenance and repair of energy efficiency equipment
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
7.5 CCM/CCA - Installation, maintenance and repair of instruments and devices for measuring, regulation and controlling energy performance of buildings
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Limited Data Preview
You are viewing a limited preview of SCHOTT Pharma AG & Co’s EU Taxonomy dataset. The full dataset, available for download, includes eligibility and alignment metrics for turnover, CAPEX, and OPEX across all EU Taxonomy categories (A1, A2, A, B, and A+B), at both aggregate and activity level, with historical coverage back to 2023.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Used by 1,000+ teams in finance, climate, and research
Verified Sources Behind SCHOTT Pharma AG & Co’s EU Taxonomy Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore SCHOTT Pharma AG & Co’s data sources below and access millions more through our Disclosure Search.
a. SCHOTT Pharma AG & Co's Annual Report 2025
b. SCHOTT Pharma AG & Co's Annual Report 2024
c. SCHOTT Pharma AG & Co's Annual Report 2023
Insights into SCHOTT Pharma AG & Co's Revenues from Sustainable Activities
In 2025, SCHOTT Pharma AG & Co reported EU Taxonomy-eligible revenues of EUR 0, representing 0% of its total turnover. Of this amount, EUR 0 of SCHOTT Pharma AG & Co's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Insights into SCHOTT Pharma AG & Co's CAPEX from Sustainable Activities
In 2025, SCHOTT Pharma AG & Co reported EU Taxonomy-eligible CAPEX of EUR 2.15 million,representing 1.5% of its total CAPEX. Of this amount, EUR 1.14 million of SCHOTT Pharma AG & Co's CAPEX was classified as EU Taxonomy-aligned, indicating that 0.8% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
How much of SCHOTT Pharma AG & Co's capital expenditure (CAPEX) is eligible under the EU Taxonomy?
In 2025, SCHOTT Pharma AG & Co reported that EUR 2.15 million of its capital expenditure (CAPEX) was eligible under the EU Taxonomy, representing 1.5% of the company's total CAPEX. Of this amount, EUR 1.14 million (0.8% of total CAPEX) was classified as Taxonomy-aligned. This means that 0.7% of SCHOTT Pharma AG & Co's CAPEX is eligible but not aligned, indicating that these investments either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of SCHOTT Pharma AG & Co's eligible CAPEX is aligned with the EU Taxonomy?
In 2025, SCHOTT Pharma AG & Co reported that EUR 1.14 million of its CAPEX was aligned under the EU Taxonomy, representing 0.8% of its total capital investment.a
This low alignment reflects that SCHOTT Pharma AG & Co is beginning to transition its capital allocation toward greener investments, but still retains substantial opportunities for further alignment with sustainability goals.
SCHOTT Pharma AG & Co's Eligibility & Alignment Overview
SCHOTT Pharma AG & Co's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Capex
Total Taxonomy Eligible but Not Aligned A2 Capex
How is SCHOTT Pharma AG & Co's taxonomy-aligned CAPEX distributed across the EU environmental objectives?
In 2025, SCHOTT Pharma AG & Co reported that its taxonomy-aligned capital expenditure (CAPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 0.8%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much SCHOTT Pharma AG & Co is investing in climate-related solutions?
In 2025, SCHOTT Pharma AG & Co allocated EUR 1.18 million of its CAPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 0.8% of the company's total capital expenditure,indicating that SCHOTT Pharma AG & Cohas only marginally directed its capital expenditure toward climate-related activities, suggesting limited alignment with climate objectives.a
Insights into SCHOTT Pharma AG & Co's OPEX from Sustainable Activities
In 2025, SCHOTT Pharma AG & Co reported EU Taxonomy-eligible OPEX of EUR 491,900,representing 1% of its total operating expenses (OPEX). Of this amount, EUR 71,900 of SCHOTT Pharma AG & Co's OPEX was classified as EU Taxonomy-aligned, indicating that 0.1% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
How much of SCHOTT Pharma AG & Co's operational expenditure (OPEX) is eligible under the EU Taxonomy?
In 2025, SCHOTT Pharma AG & Co reported that EUR 491,900 of its operational expenditure (OPEX) was eligible under the EU Taxonomy, representing 1% of the company's total OPEX. Of this amount, EUR 71,900 (0.1% of total OPEX) was classified as Taxonomy-aligned. This means that 0.9% of SCHOTT Pharma AG & Co's OPEX is eligible but not aligned, indicating that these expenditures either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of SCHOTT Pharma AG & Co's eligible OPEX is aligned with the EU Taxonomy?
In 2025, SCHOTT Pharma AG & Co reported that EUR 71,900 of its OPEX was aligned under the EU Taxonomy, representing 0.1% of its total operational expenditure.a
This low alignment reflects limited operational focus on green activities, suggesting that sustainability considerations have yet to be fully integrated into core operating processes.
SCHOTT Pharma AG & Co's Eligibility & Alignment Overview
SCHOTT Pharma AG & Co's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Opex
Total Taxonomy Eligible but Not Aligned A2 Opex
How is SCHOTT Pharma AG & Co's taxonomy-aligned OPEX distributed across the EU environmental objectives?
In 2025, SCHOTT Pharma AG & Co reported that its taxonomy-aligned operational expenditure (OPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 0.1%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much of SCHOTT Pharma AG & Co's operational budget supports climate-related solutions?
In 2025, SCHOTT Pharma AG & Co allocated EUR 48,458 of its OPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 0.1% of the company's total OPEX,indicating that SCHOTT Pharma AG & Cohas only a limited share of operational expenditure aligned with climate goals, signaling early-stage or minimal integration of climate objectives into its routine activities.a
Want Full Access to SCHOTT Pharma AG & Co's EU Taxonomy Dataset?
b
a
c
a
c
a
b
c
a
b
c
a
a